Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 11/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.57 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213246 | 0.90 | MAOB (0.55) | MAOBGRM5PARP10FFAR1MAOA | |
| SCHEMBL4208749 | 0.89 | MAOB (0.53) | MAOBGRM5FFAR1MAOA | |
| SCHEMBL4208728 | 0.89 | MAOB (0.54) | MAOBGRM5PARP10FFAR1MAOA | |
| SCHEMBL4208348 | 0.87 | MAOB (0.54) | MAOBGRM5FFAR1MAOANR4A2 | |
| SCHEMBL4210202 | 0.86 | MAOB (0.59) | MAOBGRM5PARP10FFAR1MAOA | |
| SCHEMBL4209986 | 0.84 | MAOB (0.57) | MAOBGRM5PARP10FFAR1MAOA | |
| SCHEMBL4208377 | 0.82 | MAOB (0.52) | MAOBGRM5FFAR1MAOANR4A2 | |
| SCHEMBL4211601 | 0.81 | MAOB (0.56) | MAOBGRM5FFAR1MAOA | |
| SCHEMBL2883778 | 0.81 | FFAR1 (0.62) | MAOBGRM5FFAR1MAOA | |
| SCHEMBL4208226 | 0.80 | MAOB (0.54) | MAOBGRM5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | claimed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | claimed |
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2009-01-01 | — | — | US | disclosed |
| EP-1863784-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006102958-A1 | SUBSTITUTED AMINOALKYL- AND AMIDOALKYL-BENZOPYRAN DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005436-A1 | Substituted Aminoalkyl- and Amidoalkyl-Benzopyran Derivatives | MAOB, MAOA, AOC3 | MAOB 1/4885GRM5 1809/4885PARP10 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.